Recursion Pharmaceuticals, Inc. (RXRX) Misses Q2 EPS by 1c
Tweet
Share
E-mailGet Alerts RXRX Hot Sheet
Join SI Premium – FREE
Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) reported Q2 EPS of ($0.25), $0.01 worse than the analyst estimate of ($0.24). Revenue for the quarter came in at $7.67 million versus the consensus estimate of $12.15 million.
For earnings history and earnings-related data on Recursion Pharmaceuticals, Inc. (RXRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- ICU Medical (ICUI) Tops Q2 EPS by 46c ; Offers Guidance
- Groupon (GRPN) Reports In-Line Q2 EPS ; Offers Guidance
- Funko (FNKO) Tops Q2 EPS by 46c
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
